Citations (85)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Maj-Britt Jensen, Jens Fabricius Krarup, Torben Palshof, Henning T. Mouridsen & Bent Ejlertsen. (2018) Two years of tamoxifen or no adjuvant systemic therapy for patients with high-risk breast cancer: long-term follow-up of the Copenhagen breast cancer trial. Acta Oncologica 57:1, pages 26-30.
Read now
Read now
Johan Rosell, Bo Nordenskjöld, Nils-Olof Bengtsson, Tommy Fornander, Thomas Hatschek, Henrik Lindman, Per-Olof Malmström, Arne Wallgren, Olle Stål & John Carstensen. (2017) Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen. Acta Oncologica 56:4, pages 614-617.
Read now
Read now
Thomas P. Ahern, Deirdre P. Cronin-Fenton, Timothy L. Lash, Henrik Toft Sørensen, Anne Gulbech Ording, Stephen J. Hamilton-Dutoit & Ylva Hellberg. (2016) Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study. Acta Oncologica 55:6, pages 734-741.
Read now
Read now
Bruno M Simões & Maria dM Vivanco. (2011) Cancer Stem Cells in the Human Mammary Gland and Regulation of Their Differentiation by Estrogen. Future Oncology 7:8, pages 995-1006.
Read now
Read now
Emilio Bria, Paolo Carlini, Federica Cuppone, Vanja Vaccaro, Michele Milella & Francesco Cognetti. (2010) Early recurrence risk: aromatase inhibitors versus tamoxifen. Expert Review of Anticancer Therapy 10:8, pages 1239-1253.
Read now
Read now
Michael Untch & Christoph Thomssen. (2010) Clinical Practice Decisions in Endocrine Therapy. Cancer Investigation 28:sup1, pages 4-13.
Read now
Read now
Andrew Robinson. (2009) A review of the use of exemestane in early breast cancer. Therapeutics and Clinical Risk Management 5, pages 91-98.
Read now
Read now
Articles from other publishers (78)
L.W. de Boo, K. Jóźwiak, N.D. Ter Hoeve, P.J. van Diest, M. Opdam, Y. Wang, M.K. Schmidt, V. de Jong, S. Kleiterp, S. Cornelissen, D. Baars, R.H.T. Koornstra, E.D. Kerver, T. van Dalen, A.D. Bins, A. Beeker, S.M. van den Heiligenberg, P.C. de Jong, S.D. Bakker, R.C. Rietbroek, I.R. Konings, R. Blankenburgh, R.M. Bijlsma, A.L.T. Imholz, N. Stathonikos, W. Vreuls, J. Sanders, E.H. Rosenberg, E.A. Koop, Z. Varga, C.H.M. van Deurzen, A.L. Mooyaart, A. Córdoba, E. Groen, J. Bart, S.M. Willems, V. Zolota, J. Wesseling, A. Sapino, E. Chmielik, A. Ryska, A. Broeks, A.C. Voogd, E. van der Wall, S. Siesling, R. Salgado, G.M.H.E. Dackus, M. Hauptmann, M. Kok & S.C. Linn. (2024) Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer. ESMO Open 9:3, pages 102923.
Crossref
Crossref
Nisha S. Thomas, Rebecca L. Scalzo & Elizabeth A. Wellberg. (2023) Diabetes mellitus in breast cancer survivors: metabolic effects of endocrine therapy. Nature Reviews Endocrinology 20:1, pages 16-26.
Crossref
Crossref
Anna Nordenskjöld, Helena Fohlin, Johan Rosell, Nils-Olof Bengtsson, Tommy Fornander, Thomas Hatschek, Henrik Lindman, Per Malmström, Lisa Rydén, Arne Wallgren, Olle Stål & Bo Nordenskjöld. (2023) Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy. The Breast 71, pages 63-68.
Crossref
Crossref
Qian Cao, Jinchun Feng, Yihai Wang, Munire Mushajiang & Xiuqing Ai. (2023) Compare the impact of simultaneous integrated boost radiotherapy and conventional radiotherapy with sequential boost to early breast cancer patients. Journal of Radiation Research and Applied Sciences 16:3, pages 100620.
Crossref
Crossref
Lyvia Neves Rebello Alves, Débora Dummer Meira, Luiza Poppe Merigueti, Matheus Correia Casotti, Diego do Prado Ventorim, Jucimara Ferreira Figueiredo Almeida, Valdemir Pereira de Sousa, Marllon Cindra Sant’Ana, Rahna Gonçalves Coutinho da Cruz, Luana Santos Louro, Gabriel Mendonça Santana, Thomas Erik Santos Louro, Rhana Evangelista Salazar, Danielle Ribeiro Campos da Silva, Aléxia Stefani Siqueira Zetum, Raquel Silva dos Reis Trabach, Flávia Imbroisi Valle Errera, Flávia de Paula, Eldamária de Vargas Wolfgramm dos Santos, Elizeu Fagundes de Carvalho & Iúri Drumond Louro. (2023) Biomarkers in Breast Cancer: An Old Story with a New End. Genes 14:7, pages 1364.
Crossref
Crossref
D. Yu. Belousov & A. E. Cheberda. (2023) Adjuvant hormone therapy in early-stage estrogen-positive breast cancer: a systematic review and network meta-analysis. Patient-Oriented Medicine and Pharmacy 1:2, pages 75-84.
Crossref
Crossref
Ibrahim Alfaris, Jamil Asselah, Haya Aziz, Nathaniel Bouganim & Negareh Mousavi. (2023) The Cardiovascular Risks Associated with Aromatase Inhibitors, Tamoxifen, and GnRH Agonists in Women with Breast Cancer. Current Atherosclerosis Reports 25:4, pages 145-154.
Crossref
Crossref
Jinani Jayasekera, Amy Zhao, Clyde Schechter, Kathryn Lowry, Jennifer M. Yeh, Marc D. Schwartz, Suzanne O'Neill, Karen J. Wernli, Natasha Stout, Jeanne Mandelblatt, Allison W. Kurian & Claudine Isaacs. (2023) Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor–Positive Breast Cancer. Journal of Clinical Oncology 41:4, pages 859-870.
Crossref
Crossref
Giovanna Garufi, Luisa Carbognin, Concetta Arcanà, Sara Parola, Anna Ventriglia, Antonio Doronzo, Mattia Garutti, Armando Orlandi, Antonella Palazzo, Alessandra Fabi, Emilio Bria, Giampaolo Tortora, Grazia Arpino, Mario Giuliano, Lucia Del Mastro, Michelino De Laurentiis & Fabio Puglisi. (2022) Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?. Cancer Treatment Reviews 110, pages 102454.
Crossref
Crossref
Ki-Jin Ryu, Min Sun Kim, Ji Yoon Lee, Seunghyun Nam, Hye Gyeong Jeong, Tak Kim & Hyuntae Park. (2022) Risk of Endometrial Polyps, Hyperplasia, Carcinoma, and Uterine Cancer After Tamoxifen Treatment in Premenopausal Women With Breast Cancer. JAMA Network Open 5:11, pages e2243951.
Crossref
Crossref
Jenny Pousette, Annelie Johansson, Carolin Jönsson, Tommy Fornander, Linda S. Lindström, Hans Olsson & Gizeh Perez-Tenorio. (2022) Prognostic and Predictive Significance of Stromal Tumor-Infiltrating Lymphocytes (sTILs) in ER-Positive/HER2−Negative Postmenopausal Breast Cancer Patients. Cancers 14:19, pages 4844.
Crossref
Crossref
Annelie Johansson, Nancy Y. Yu, Adina Iftimi, Nicholas P. Tobin, Laura 't Veer, Bo Nordenskjöld, Christopher C. Benz, Tommy Fornander, Gizeh Perez‐Tenorio, Olle Stål, Laura J. Esserman, Christina Yau & Linda S. Lindström. (2022) Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signature. International Journal of Cancer 150:12, pages 2072-2082.
Crossref
Crossref
Whitney E. Zahnd, Radhika Ranganathan, Swann Arp Adams & Oluwole A. Babatunde. (2022) Sociodemographic disparities in molecular testing for breast cancer. Cancer Causes & Control 33:6, pages 843-859.
Crossref
Crossref
Ankit Desai, Musaab Yassin, Axel Cayetano, Tharu Tharakan, Channa N. Jayasena & Suks Minhas. (2022) Understanding and managing the suppression of spermatogenesis caused by testosterone replacement therapy (TRT) and anabolic–androgenic steroids (AAS). Therapeutic Advances in Urology 14, pages 175628722211050.
Crossref
Crossref
Carina Strell & Arne Östman. 2022. Biomarkers of the Tumor Microenvironment. Biomarkers of the Tumor Microenvironment
125
138
.
Anna-Karin Wennstig, Charlotta Wadsten, Hans Garmo, Mikael Johansson, Irma Fredriksson, Carl Blomqvist, Lars Holmberg, Greger Nilsson & Malin Sund. (2021) Risk of primary lung cancer after adjuvant radiotherapy in breast cancer—a large population-based study. npj Breast Cancer 7:1.
Crossref
Crossref
Huma Dar, Annelie Johansson, Anna Nordenskjöld, Adina Iftimi, Christina Yau, Gizeh Perez-Tenorio, Christopher Benz, Bo Nordenskjöld, Olle Stål, Laura J. Esserman, Tommy Fornander & Linda S. Lindström. (2021)
Assessment of 25-Year Survival of Women With Estrogen Receptor–Positive/
ERBB2
-Negative Breast Cancer Treated With and Without Tamoxifen Therapy
. JAMA Network Open 4:6, pages e2114904.
Crossref
Crossref
Johanna Holm, Nancy Yiu-Lin Yu, Annelie Johansson, Alexander Ploner, Per Hall, Linda Sofie Lindström & Kamila Czene. (2021) Concordance of Immunohistochemistry-Based and Gene Expression-Based Subtyping in Breast Cancer. JNCI Cancer Spectrum 5:1.
Crossref
Crossref
Sanne Løkkegaard, Daniel Elias, Carla L. Alves, Martin V. Bennetzen, Anne-Vibeke Lænkholm, Martin Bak, Morten F. Gjerstorff, Lene E. Johansen, Henriette Vever, Christina Bjerre, Tove Kirkegaard, Bo Nordenskjöld, Tommy Fornander, Olle Stål, Linda S. Lindström, Laura J. Esserman, Anne E. Lykkesfeldt, Jens S. Andersen, Rikke Leth-Larsen & Henrik J. Ditzel. (2021) MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit. npj Breast Cancer 7:1.
Crossref
Crossref
Diego Barba, Ariana León-Sosa, Paulina Lugo, Daniela Suquillo, Fernando Torres, Frederic Surre, Lionel Trojman & Andrés Caicedo. (2021) Breast cancer, screening and diagnostic tools: All you need to know. Critical Reviews in Oncology/Hematology 157, pages 103174.
Crossref
Crossref
Jutta Engel, Gabriele Schubert-Fritschle, Rebecca Emeny & Dieter Hölzel. (2020) Breast cancer: are long-term and intermittent endocrine therapies equally effective?. Journal of Cancer Research and Clinical Oncology 146:8, pages 2041-2049.
Crossref
Crossref
Natalie M. Ertz-Archambault, Lana B. Rogoff, Heidi E. Kosiorek, Brenda J. Ernst, Karen S. Anderson, Barbara A. Pockaj, Richard J. Gray & Donald W. Northfelt. (2019) Depomedroxyprogesterone acetate therapy for hot flashes in survivors of breast cancer: no unfavorable impact on recurrence and survival. Supportive Care in Cancer 28:5, pages 2139-2143.
Crossref
Crossref
Helena Fohlin, Tove Bekkhus, Josefine Sandstr�m, Tommy� Fornander, Bo Nordenskj�ld, John Carstensen & Olle St�l. (2020) Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor‑positive/progesterone receptor‑negative breast cancer. Molecular and Clinical Oncology.
Crossref
Crossref
Helena Fohlin, Tove Bekkhus, Josefine Sandstr�m, Tommy Fornander, Bo Nordenskj�ld, John Carstensen & Olle St�l. (2019) RAB6C is an independent prognostic factor of estrogen receptor‑positive/progesterone receptor‑negative breast cancer. Oncology Letters.
Crossref
Crossref
Nancy Y. Yu, Adina Iftimi, Christina Yau, Nicholas P. Tobin, Laura van ’t Veer, Katherine A. Hoadley, Christopher C. Benz, Bo Nordenskjöld, Tommy Fornander, Olle Stål, Kamila Czene, Laura J. Esserman & Linda S. Lindström. (2019) Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer. JAMA Oncology 5:9, pages 1304.
Crossref
Crossref
Juliet Richman & Mitch Dowsett. (2018) Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer. Nature Reviews Clinical Oncology 16:5, pages 296-311.
Crossref
Crossref
Delal Akdeniz, Marjanka K. Schmidt, Caroline M. Seynaeve, Danielle McCool, Daniele Giardiello, Alexandra J. van den Broek, Michael Hauptmann, Ewout W. Steyerberg & Maartje J. Hooning. (2019) Risk factors for metachronous contralateral breast cancer: A systematic review and meta-analysis. The Breast 44, pages 1-14.
Crossref
Crossref
Elin Karlsson, Cynthia Veenstra, Jon Gårsjö, Bo Nordenskjöld, Tommy Fornander & Olle Stål. (2018) PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer. Journal of Cancer Research and Clinical Oncology 145:3, pages 599-607.
Crossref
Crossref
Michelle Jacobson, Marcus Bernardini, Mara L. Sobel, Raymond H. Kim, Jeanna McCuaig & Lisa Allen. (2018) No 366 - Prise en charge gynécologique du cancer du sein et de l'ovaire héréditaire. Journal of Obstetrics and Gynaecology Canada 40:11, pages 1511-1527.
Crossref
Crossref
Michelle Jacobson, Marcus Bernardini, Mara L. Sobel, Raymond H. Kim, Jeanna McCuaig & Lisa Allen. (2018) No. 366-Gynaecologic Management of Hereditary Breast and Ovarian Cancer. Journal of Obstetrics and Gynaecology Canada 40:11, pages 1497-1510.
Crossref
Crossref
Linda S Lindström, Christina Yau, Kamila Czene, Carlie K Thompson, Katherine A Hoadley, Laura J van't Veer, Ron Balassanian, John W Bishop, Philip M Carpenter, Yunn-Yi Chen, Brian Datnow, Farnaz Hasteh, Gregor Krings, Fritz Lin, Yanhong Zhang, Bo Nordenskjöld, Olle Stål, Christopher C Benz, Tommy Fornander, Alexander D Borowsky & Laura J Esserman. (2018) Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer. JNCI: Journal of the National Cancer Institute 110:7, pages 726-733.
Crossref
Crossref
Josefine Bostner, Anya Alayev, Adi Y. Berman, Tommy Fornander, Bo Nordenskjöld, Marina K. Holz & Olle Stål. (2017) Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment 168:1, pages 17-27.
Crossref
Crossref
Arne Östman. (2017) PDGF receptors in tumor stroma: Biological effects and associations with prognosis and response to treatment. Advanced Drug Delivery Reviews 121, pages 117-123.
Crossref
Crossref
David M. Hyams, Eric Schuur, Javier Angel Aristizabal, Juan Enrique Bargallo Rocha, Cesar Cabello, Roberto Elizalde, Laura García‐Estévez, Henry L. Gomez, Artur Katz & Aníbal Nuñez De Pierro. (2017) Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays. Journal of Surgical Oncology 115:6, pages 647-662.
Crossref
Crossref
Arne Östman. 2017. Biomarkers of the Tumor Microenvironment. Biomarkers of the Tumor Microenvironment
113
128
.
Janna Paulsson, Lisa Rydén, Carina Strell, Oliver Frings, Nicholas P Tobin, Tommy Fornander, Jonas Bergh, Göran Landberg, Olle Stål & Arne Östman. (2016) High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancer. The Journal of Pathology: Clinical Research 3:1, pages 38-43.
Crossref
Crossref
Edoardo Colzani, Mark Clements, Anna L V Johansson, Annelie Liljegren, Wei He, Judith Brand, Jan Adolfsson, Tommy Fornander, Per Hall & Kamila Czene. (2016) Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study. British Journal of Cancer 115:11, pages 1400-1407.
Crossref
Crossref
Anna Nordenskjöld, Helena Fohlin, Tommy Fornander, Britta Löfdahl, Lambert Skoog & Olle Stål. (2016) Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer. Breast Cancer Research and Treatment 160:2, pages 313-322.
Crossref
Crossref
Amity Platt, Zuping Xia, Ying Liu, Gang Chen & Philip Lazarus. (2016) Impact of nonsynonymous single nucleotide polymorphisms on in-vitro metabolism of exemestane by hepatic cytosolic reductases. Pharmacogenetics and Genomics 26:8, pages 370-380.
Crossref
Crossref
Cynthia Veenstra, Gizeh Pérez-Tenorio, Anna Stelling, Elin Karlsson, Sanam Mirwani Mirwani, Bo Nordensköljd, Tommy Fornander & Olle Stål. (2016) Met and its ligand HGF are associated with clinical outcome in breast cancer. Oncotarget 7:24, pages 37145-37159.
Crossref
Crossref
Subrata Manna, Josefine Bostner, Yang Sun, Lance D. Miller, Anya Alayev, Naomi S. Schwartz, Elin Lager, Tommy Fornander, Bo Nordenskjöld, Jane J. Yu, Olle Stål & Marina K. Holz. (2016) ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer. Clinical Cancer Research 22:6, pages 1421-1431.
Crossref
Crossref
Erik Hilborn, Jelena Gacic, Tommy Fornander, Bo Nordenskjöld, Olle Stål & Agneta Jansson. (2016) Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer. British Journal of Cancer 114:3, pages 248-255.
Crossref
Crossref
ANNA GÖTHLIN EREMO, ELISABET TINA, PIA WEGMAN, OLLE STÅL, KARIN FRANSÉN, TOMMY FORNANDER & STEN WINGREN. (2015) HER4 tumor expression in breast cancer patients randomized to treatment with or without tamoxifen. International Journal of Oncology 47:4, pages 1311-1320.
Crossref
Crossref
Elin Karlsson, Cynthia Veenstra, Shad Emin, Chhanda Dutta, Gizeh Pérez-Tenorio, Bo Nordenskjöld, Tommy Fornander & Olle Stål. (2015) Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer. Breast Cancer Research and Treatment 153:1, pages 31-40.
Crossref
Crossref
Raquel C Martinez-Chacin, Megan Keniry & Robert K Dearth. (2014) Analysis of high fat diet induced genes during mammary gland development: identifying role players in poor prognosis of breast cancer. BMC Research Notes 7:1.
Crossref
Crossref
Helena Aguilar, Ander Urruticoechea, Pasi Halonen, Kazuma Kiyotani, Taisei Mushiroda, Xavier Barril, Jordi Serra-Musach, Abul Islam, Livia Caizzi, Luciano Di Croce, Ekaterina Nevedomskaya, Wilbert Zwart, Josefine Bostner, Elin Karlsson, Gizeh Pérez Tenorio, Tommy Fornander, Dennis C Sgroi, Rafael Garcia-Mata, Maurice PHM Jansen, Nadia García, Núria Bonifaci, Fina Climent, María Teresa Soler, Alejo Rodríguez-Vida, Miguel Gil, Joan Brunet, Griselda Martrat, Laia Gómez-Baldó, Ana I Extremera, Agnes Figueras, Josep Balart, Robert Clarke, Kerry L Burnstein, Kathryn E Carlson, John A Katzenellenbogen, Miguel Vizoso, Manel Esteller, Alberto Villanueva, Ana B Rodríguez-Peña, Xosé R Bustelo, Yusuke Nakamura, Hitoshi Zembutsu, Olle Stål, Roderick L Beijersbergen & Miguel Angel Pujana. (2014) VAV3 mediates resistance to breast cancer endocrine therapy. Breast Cancer Research 16:3.
Crossref
Crossref
Martin Sjöström, Linda Hartman, Dorthe Grabau, Tommy Fornander, Per Malmström, Bo Nordenskjöld, Dennis C. Sgroi, Lambert Skoog, Olle Stål, L. M. Fredrik Leeb-Lundberg & Mårten Fernö. (2014) Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer. Breast Cancer Research and Treatment 145:1, pages 61-71.
Crossref
Crossref
Erik Hilborn, Tove Sivik, Tommy Fornander, Olle Stål, Bo Nordenskjöld & Agneta Jansson. (2014) C–X–C ligand 10 and C–X–C receptor 3 status can predict tamoxifen treatment response in breast cancer patients. Breast Cancer Research and Treatment 145:1, pages 73-82.
Crossref
Crossref
Karin Beelen, Mark Opdam, Tesa M Severson, Rutger HT Koornstra, Andrew D Vincent, Jelle Wesseling, Jettie J Muris, Els MJJ Berns, Jan B Vermorken, Paul J van Diest & Sabine C Linn. (2014) PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients. Breast Cancer Research 16:1.
Crossref
Crossref
Elin Karlsson, Gizeh Pérez-Tenorio, Risul Amin, Josefine Bostner, Lambert Skoog, Tommy Fornander, Dennis C Sgroi, Bo Nordenskjöld, Anna-Lotta Hallbeck & Olle Stål. (2013) The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials. Breast Cancer Research 15:5.
Crossref
Crossref
Dennis C Sgroi, Ivana Sestak, Jack Cuzick, Yi Zhang, Catherine A Schnabel, Brock Schroeder, Mark G Erlander, Anita Dunbier, Kally Sidhu, Elena Lopez-Knowles, Paul E Goss & Mitch Dowsett. (2013) Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. The Lancet Oncology 14:11, pages 1067-1076.
Crossref
Crossref
Yi Zhang, Catherine A. Schnabel, Brock E. Schroeder, Piiha-Lotta Jerevall, Rachel C. Jankowitz, Tommy Fornander, Olle Stål, Adam M. Brufsky, Dennis Sgroi & Mark G. Erlander. (2013) Breast Cancer Index Identifies Early-Stage Estrogen Receptor–Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence. Clinical Cancer Research 19:15, pages 4196-4205.
Crossref
Crossref
M. Weiner, L. Skoog, T. Fornander, B. Nordenskjöld, D.C. Sgroi & O. Stål. (2013) Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer. Annals of Oncology 24:8, pages 1994-1999.
Crossref
Crossref
Günter Emons, Andreas Günthert, Falk C. Thiel, Oumar Camara, Hans-Georg Strauss, Georg-Peter Breitbach, Heinz Kölbl, Toralf Reimer, Dominique Finas & Klaus Rensing. (2013) Phase II study of fulvestrant 250mg/month in patients with recurrent or metastatic endometrial cancer: A study of the Arbeitsgemeinschaft Gynäkologische Onkologie. Gynecologic Oncology 129:3, pages 495-499.
Crossref
Crossref
ANNA GÖTHLIN EREMO, PIA WEGMAN, OLLE STÅL, BO NORDENSKJÖLD, TOMMY FORNANDER & STEN WINGREN. (2013) Wwox expression may predict benefit from adjuvant tamoxifen in randomized breast cancer patients. Oncology Reports 29:4, pages 1467-1474.
Crossref
Crossref
Josefine Bostner, Elin Karlsson, Muneeswaran J. Pandiyan, Hanna Westman, Lambert Skoog, Tommy Fornander, Bo Nordenskjöld & Olle Stål. (2012) Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit. Breast Cancer Research and Treatment 137:2, pages 397-406.
Crossref
Crossref
Tove Sivik, Cecilia Gunnarsson, Tommy Fornander, Bo Nordenskjöld, Lambert Skoog, Olle Stål & Agneta Jansson. (2012) 17β-Hydroxysteroid Dehydrogenase Type 14 Is a Predictive Marker for Tamoxifen Response in Oestrogen Receptor Positive Breast Cancer. PLoS ONE 7:7, pages e40568.
Crossref
Crossref
Rachel C Jankowitz, Kristine Cooper, Mark G Erlander, Xiao-Jun Ma, Nicole C Kesty, Hongying Li, Mamatha Chivukula & Adam Brufsky. (2011) Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer. Breast Cancer Research 13:5.
Crossref
Crossref
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. The Lancet 378:9793, pages 771-784.
Crossref
Crossref
Gizeh Pérez-Tenorio, Elin Karlsson, Marie Ahnström Waltersson, Birgit Olsson, Birgitta Holmlund, Bo Nordenskjöld, Tommy Fornander, Lambert Skoog & Olle Stål. (2010) Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer. Breast Cancer Research and Treatment 128:3, pages 713-723.
Crossref
Crossref
Allan HackshawMichael RoughtonSharon ForsythKathryn MonsonKrystyna ReczkoRichard SainsburyMichael Baum. (2011) Long-Term Benefits of 5 Years of Tamoxifen: 10-Year Follow-Up of a Large Randomized Trial in Women at Least 50 Years of Age With Early Breast Cancer. Journal of Clinical Oncology 29:13, pages 1657-1663.
Crossref
Crossref
P-L Jerevall, X-J Ma, H Li, R Salunga, N C Kesty, M G Erlander, D C Sgroi, B Holmlund, L Skoog, T Fornander, B Nordenskjöld & O Stål. (2011) Prognostic utility of HOXB13 : IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. British Journal of Cancer 104:11, pages 1762-1769.
Crossref
Crossref
Mahmoud R. Khoshnoud, Britta Löfdahl, Helena Fohlin, Tommy Fornander, Olle Stål, Lambert Skoog, Jonas Bergh & Bo Nordenskjöld. (2010) Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen. Breast Cancer Research and Treatment 126:2, pages 421-430.
Crossref
Crossref
Allan L. Covens, Virginia Filiaci, Deborah Gersell, Christopher V. Lutman, Albert Bonebrake & Yi-Chun Lee. (2011) Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: A Gynecologic Oncology Group Study. Gynecologic Oncology 120:2, pages 185-188.
Crossref
Crossref
Christos J. Markopoulos. (2010) Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of AI trials. Cancer and Metastasis Reviews 29:4, pages 581-594.
Crossref
Crossref
Alfonso Sánchez-Muñz, Nuria Ribelles & Emilio Alba. (2010) Optimal adjuvant hormonal therapy in postmenopausal women with hormone-receptor-positive early breast cancer: have we answered the question?. Clinical and Translational Oncology 12:9, pages 614-620.
Crossref
Crossref
Piiha-Lotta Jerevall, Agneta Jansson, Tommy Fornander, Lambert Skoog, Bo Nordenskjöld & Olle Stål. (2010) Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer. Breast Cancer Research 12:4.
Crossref
Crossref
Josefine Bostner, Lambert Skoog, Tommy Fornander, Bo Nordenskjöld & Olle Stål. (2010) Estrogen Receptor-α Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer. Clinical Cancer Research 16:5, pages 1624-1633.
Crossref
Crossref
Amanda I. Phipps & Christopher I. Li. 2010. Breast Cancer Epidemiology. Breast Cancer Epidemiology
21
46
.
Masakazu Toi, Hiroyasu Yamashiro & Wakako Tsuji. (2009) Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer. Breast Cancer 16:3, pages 207-218.
Crossref
Crossref
Agneta Jansson, Lovisa Delander, Cecilia Gunnarsson, Tommy Fornander, Lambert Skoog, Bo Nordenskjöld & Olle Stål. (2009) Ratio of 17HSD1 to 17HSD2 Protein Expression Predicts the Outcome of Tamoxifen Treatment in Postmenopausal Breast Cancer Patients. Clinical Cancer Research 15:10, pages 3610-3616.
Crossref
Crossref
C. A. Gabriel, J. Tigges-Cardwell, J. Stopfer, J. Erlichman, K. Nathanson & S. M. Domchek. (2008) Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy. Familial Cancer 8:1, pages 23-28.
Crossref
Crossref
Anne Fletcher, Jessica Reiseger, Katerina Vlahos, Natalie Seach, Jarrod Dudakov, Ann Chidgey & Richard Boyd. 2009. Handbook on Immunosenescence. Handbook on Immunosenescence
1571
1609
.
Paul E. Goss. (2008) Extending the benefits of adjuvant therapy in early HR+ breast cancer. Breast Cancer Research and Treatment 112:S1, pages 45-52.
Crossref
Crossref
R. Calderon-Margalit, Y. Friedlander, R. Yanetz, K. Kleinhaus, M. C. Perrin, O. Manor, S. Harlap & O. Paltiel. (2008) Cancer Risk After Exposure to Treatments for Ovulation Induction. American Journal of Epidemiology 169:3, pages 365-375.
Crossref
Crossref
Andrew L. Cooke, Colleen Metge, Lisa Lix, Heather J. Prior & William D. Leslie. (2008) Tamoxifen Use and Osteoporotic Fracture Risk: A Population-Based Analysis. Journal of Clinical Oncology 26:32, pages 5227-5232.
Crossref
Crossref
J. Michael Dixon. (2008) Reducing early recurrence with adjuvant aromatase inhibitors: What is the evidence?. The Breast 17:4, pages 353-360.
Crossref
Crossref
Christa K Baumann & Monica Castiglione-Gertsch. (2007) Estrogen Receptor Modulators and Down Regulators. Drugs 67:16, pages 2335-2353.
Crossref
Crossref